Menu
Recruiting NCT06852079

Safety & Efficacy of Qurs e Fishar in Mild to Moderate Hypertensive Patients in Pakistan

Phase III Interventional Hypertension

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Qurs e Fishar.
Who it may be relevant to
Registry conditions: Hypertension. Basic parameters: 30 years — 60 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Pakistan
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

The herbal medicine Qurs-e-Fishar to treat mild to moderate High blood pressure or hypertension comprises of Rauwolfia serpentina. A product of Hamdard Laboratories (Waqf) Pakistan. A Phase III Safety \& Efficacy Open-label, Single-Arm, Interventional, Multicenter, Study in mild to moderate hypertensive, adults (30 to 60 years of age) prescribed with study product for 12 weeks (84 days). Primary End Points: 1. Reduction in diastolic blood pressure less than 130 / 80 mmHg at the end of the study period (accepted by WHO) or if there was a fall of 20 / 10 mmHg or more in diastolic blood pressure as compared to baseline. 2. Type, frequency and severity of ADRs during the study period. Secondary End Points: 1\. Compliance of the prescribed study medication.

Interventions

  • Other Qurs e Fishar
    Qurs e Fishar is a herbal remedy for Hypertension

Primary outcome measures

  • Blood Pressure [Time frame: 12 weeks]

Eligibility criteria

Inclusion criteria

  • Ability to sign ICD
  • Participant(s) are willing and able to fulfill the requirements of the study protocol
  • Mild to moderate hypertensive
  • Mild hypertension range (140-159/90-99 mm Hg)
  • Moderate hypertension range (160-179/100-109 mm Hg)
  • Be between the age of 30 to 60 year

Exclusion criteria

  • Patients with recent history of following will be excluded:
  • Severe hypertension,
  • Congestive cardiac failure,
  • Left ventricular failure,
  • Myocardial ischemia,
  • Renal failure or
  • Cerebrovascular accidents

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Treatment

Study locations

Pakistan · 1 center
  • Taj Medical Complex, Hamdard University Hospital — Karachi

Identifiers

NCT: NCT06852079 · QF-HLWP

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗